Examining a New Nanocell Therapy for Treating Advanced Pancreatic Cancer
NCT07049055 · RecruitingThis trial is looking at a new treatment for pancreatic cancer that has spread. Researchers want to see if a special type of nanocell therapy, combined with two common chemotherapy drugs, can improve outcomes. The goal is to find out if this combination is safe and how well it works compared to the standard therapy alone.
Locations and contact
This trial is running at 4 locations in the United States. 3 of them are currently recruiting.
United States4 locations · 3 recruiting
- Atlantic HealthSummit, New JerseyRecruiting
- Columbia University Irving Medical CenterNew York, New YorkRecruiting
- Taylor Cancer CenterMaumee, OhioRecruiting
- Chan Soon-Shiong Institute for MedicineEl Segundo, CaliforniaActive Not Recruiting
Who can join
The trial is open to adults aged 18 and older with confirmed metastatic pancreatic adenocarcinoma. Participants must have measurable disease and tumors that express a specific protein. They should have completed first-line therapy and must meet certain health criteria. The trial team will confirm if each person is eligible to join.
What happens during the trial
Participants will be placed into two groups by chance. One group will receive the new nanocell therapy combined with standard treatment. The other group will receive standard treatment with a placebo, which looks like the real medicine but has no active ingredients. Everyone will have regular visits for treatment and monitoring during the trial.
The trial team
The trial is sponsored by Engeneic Pty Limited, with collaboration from the Herbert Irving Comprehensive Cancer Center. The lead investigator is Dr. Linda Y. Wu from Columbia University Medical Center, along with Dr. Jennifer MacDiarmid and Dr. Himanshu Brahmbhatt from Engeneic.
Important dates
The trial started on January 12, 2026, and is expected to finish in September 2028. It is currently recruiting new participants.
Additional information
This trial is registered under the ID NCT07049055. It is in Phase I/II, which means it is testing both safety and how well the treatment works. The trial is FDA-regulated and aims to include 144 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →